Pemetrexed

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Nonsquamous Non-Small Cell Neoplasm of Lung

Conditions

Nonsquamous Non-Small Cell Neoplasm of Lung, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer Stage IIIB

Trial Timeline

Dec 1, 2011 → Sep 1, 2013

NCT ID

NCT01473563

About Pemetrexed

Pemetrexed is a phase 2 stage product being developed by Eli Lilly for Nonsquamous Non-Small Cell Neoplasm of Lung. The current trial status is completed. This product is registered under clinical trial identifier NCT01473563. Target conditions include Nonsquamous Non-Small Cell Neoplasm of Lung, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer Stage IIIB.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00035061	Phase 2	Completed	—	—	Urologic Neoplasms
NCT03955042	Phase 1	Completed	Sep 6, 2019	Jan 18, 2023	Chordoma
NCT01473563	Phase 2	Completed	Dec 1, 2011	Sep 1, 2013	Nonsquamous Non-Small Cell Neoplasm of Lung
NCT00916630	Phase 1	Completed	Jan 1, 2009	Sep 1, 2015	Central Nervous System Lymphoma
NCT00732303	Phase 2	Terminated	Jan 1, 2009	Dec 1, 2010	Non-Small Cell Lung Cancer
NCT00864513	Phase 2	Terminated	Oct 1, 2007	Jul 1, 2009	Pancreas Cancer
NCT00520936	Phase 2	Completed	Sep 1, 2007	Feb 1, 2010	Osteosarcoma
NCT00523419	Phase 2	Completed	Sep 1, 2007	Jun 1, 2010	Osteosarcoma
NCT00540241	Pre-clinical	Completed	Sep 1, 2007	Mar 1, 2010	Non Small Cell Lung Cancer
NCT00497770	Pre-clinical	Completed	Feb 1, 2007	Mar 1, 2011	Lung Neoplasms
NCT00316225	Phase 2	Completed	Dec 1, 2006	Mar 1, 2009	Non-small Cell Lung Cancer
NCT00380718	Approved	Completed	Nov 1, 2006	Nov 1, 2009	Non-small Cell Lung Cancer
NCT00377520	Phase 2	Completed	Sep 1, 2006	Sep 1, 2008	Neoplasms
NCT00190918	Phase 2	Completed	Jul 1, 2006	Jul 1, 2007	Trophoblastic Neoplasms
NCT00330915	Phase 2	Completed	Jun 1, 2006	Jun 1, 2008	Rectal Neoplasms
NCT00109096	Phase 2	Completed	Jun 1, 2005	Mar 1, 2007	Ovarian Neoplasms
NCT00106002	Phase 2	Completed	Apr 1, 2005	Dec 1, 2007	Breast Cancer
NCT00216099	Phase 2	Completed	Feb 1, 2005	Mar 1, 2009	Prostate Cancer
NCT00190983	Phase 2	Completed	Feb 1, 2005	Oct 1, 2007	Cervical Intraepithelial Neoplasia
NCT00216216	Phase 2	Terminated	Jan 1, 2005	Oct 1, 2005	Small Cell Lung Cancer

Competing Products

7 competing products in Nonsquamous Non-Small Cell Neoplasm of Lung

See all competitors

Product	Company	Stage	Hype Score
Pemetrexed + Erlotinib + Pemetrexed + Erlotinib	Eli Lilly	Phase 2	52
Patritumab Deruxtecan + Platinum-based chemotherapy	Daiichi Sankyo	Phase 3	77
Pembrolizumab + Carboplatin + Cisplatin + Pemetrexed + Lenvatinib + Placebo matching lenvatinib	Eisai	Phase 3	77
Pembrolizumab + Carboplatin + Cisplatin + Pemetrexed + Lenvatinib + Placebo matching lenvatinib	Eisai	Phase 3	77
Pembrolizumab + Pemetrexed + Carboplatin + Cisplatin + Olaparib	Merck	Phase 3	77
Erlotinib	Roche	Pre-clinical	23
Pemetrexed + Carboplatin + demcizumab	Mereo BioPharma	Phase 2	44

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved